Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Biotechnology

Healthcare
$8.86 +2.49%

+$0.22 today

Market cap
$595.76M
Beta
1.48
P/E (TTM)
-8.6
EPS (TTM)
-$0.74
52W Low $5.82High $12.86

Volume 0.16M

Average 0.05M

EPRX.TO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$15.61M, compared with -$4.72M a year earlier. Trailing-twelve-month EBITDA was -$44.63M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -65.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$15.61M+4.5% QoQ
Last fiscal yearDec 2025
-$38.86M-65.9% YoY
LTMMar 2026
-$44.63M-141.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-230.8%+100.0%+330.8 pp
1 year-65.9%+100.0%+165.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

Mixed currencies · from the income statement

Latest · FY2025
(38.86M) USD
Year-over-year change
-65.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How EPRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -141.2% is the 7th highest of 8, against a peer median of +48.2%.
EPRX.TO Competitors
EBITDA for EPRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$75.52M USD-3.6%+5.1%24.7%
TSND.TOTerrAscend Corp.LTM Mar 2026$60.46M USD+510.4%—23.1%
HBP.TOHelix BioPharma Corp.LTM Apr 2026-CA$3.08M CAD+67.7%——
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026-$5.36M USD+48.2%—10.5%
PRN.TOProfound Medical Corp.LTM Mar 2026-$36.45M USD-1.4%—194.3%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-CA$40.84M CAD-681.4%—14.9%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026-$44.63M USD-141.2%——
WEED.TOCanopy Growth CorporationLTM Mar 2026-CA$63.48M CAD+86.8%—20.4%
Peer median (excluding EPRX.TO) —+48.2%+5.1%21.8%

Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue111.53K193.27K158.05K163.47K241.88K
Gross Profit(111.53K)(193.27K)(158.05K)(163.47K)(241.88K)
Gross Margin—————
Research & Development10.17M17.58M21M15.17M21.51M
Selling, General & Admin8.2M5.81M7.37M10.92M17.1M
Operating Expenses18.38M23.38M28.37M25.54M38.86M
Depreciation & Amortization111.53K193.27K158.05K163.47K241.88K
EBITDA(21.96M)(22.14M)(28.16M)(23.43M)(38.86M)
EBITDA Margin—————
Operating Income(18.47M)(23.58M)(27.78M)(25.71M)(39.11M)
Operating Margin—————
Interest Income65.73K569.32K876.96K1.1M1.44M
Interest Expense1.3M1.59M1.19M913.1K0
Other Income / Expenses(4.9M)(341.09K)(1.08M)1.2M(155.19K)
Income Before Tax(23.37M)(23.92M)(28.93M)(24.51M)(39.26M)
Pre-Tax Margin—————
Income Tax Expense00(67.51K)1.72K19.42K
Net Income(22.99M)(23.26M)(28.15M)(24.28M)(39.25M)
Net Margin—————
EPS (Basic)(1.61)(1.21)(1.19)(0.72)(1.05)
EPS (Diluted)(1.61)(1.21)(1.19)(0.72)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.